ஹபீப் டேபிள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from ஹபீப் டேபிள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In ஹபீப் டேபிள் Today - Breaking & Trending Today
BMS, Acceleron's Reblozyl shows new improvements for beta thalassemia patients pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.
Reblozyl was generally well tolerated and improvements in hemoglobin correlated with improved patient-reported outcomes over a continuous 12-week interval In the study, 89.6% of patients treated with Reblozyl remained transfusion free vs. 67.3% of patients in the placebo arm at weeks 1-24 Results featured in Presidential Symposium of European Hematology Association’s Virtual Congress as one of top six abstracts submitted Bristol Myers Squibb (NYSE: BMY) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced the first data from the Phase 2 BEYOND study evaluating Reblozyl ® (luspatercept-aamt), a first-in-class erythroid maturation agent, plus best supportive care in adult patients with non-transfusion dependent (NTD) beta thalassemia, were presented at the European Hematology Association (EHA) 2021 Virtual Congress as part of its Presidential Symposium (Abstract #S101). Results demonstrated that 77.7% of patients treated wi ....
Operator Good afternoon, ladies and gentlemen, and welcome to the Acceleron First Quarter 2021 Earnings Conference Call. [Operator Instructions] I would now like to hand the call over to Ms. Jamie Bernard, Associate Director of Investor Relations at Acceleron. Please go ahead. Jamie A. Bernard Associate Director of Investor Relations Thanks, and welcome, everyone, to our first quarter 2021 earnings call. The press release reporting our financial results in addition to the presentation for today s webcast are available on the Investors & Media page of our corporate website at www.acceleronpharma.com. Joining me on the call this afternoon are Habib Dable, our Chief Executive Officer; Kevin McLaughlin, our Chief Financial Officer; Dr. Jay Backstrom, our Head of Research and Development; Sujay Kango, our Chief Commercial Officer; and Todd James, our Senior Vice President of Corporate Affairs and Investor Relations. As a reminder, we will be making forward-lookin ....
Health Canada Approves REBLOZYL® (luspatercept), New Class of Treatment for Adult Patients Living With Myelodysplastic Syndromes apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
– Sotatercept received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) in PAH in 2019 – – In the spring of 2020, sotatercept received Breakthrough Therapy designation from the FDA and Priority Medicines (PRIME) designation from the European Medicines Agency (EMA), both in PAH –
CAMBRIDGE, Mass. (BUSINESS WIRE) Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that the European Commission (EC) has granted orphan designation to sotatercept for the treatment of patients with pulmonary arterial hypertension (PAH). “We’re thrilled at the European Commission’s decision to grant orphan designation to sotatercept in PAH,” said Habib Dable, President and Chief Executive Officer of Acceleron. “We fully intend to take advantag ....